Consolidated Balance Sheets (USD $)	Jun. 30, 2012		Dec. 31, 2011
Current assets
Cash	$ 162,440		$ 952,252
Prepaid drug product for testing	295,477		153,000
Other current assets	46,489		48,439
Total current assets	504,406		1,153,691
Other assets
Technology licenses - related party	2,500,374		2,868,877
Less Accumulated Amortization	(839,572)		(791,463)
Intangible Assets, Net (Excluding Goodwill), Total	1,660,802		2,077,414
TOTAL ASSETS	2,165,208		3,231,105
Current liabilities
Accounts payable	31,147		121,540
Accounts payable - related party	22,588		67,971
Accrued expense	86,588		46,082
Accrued expense - related party	52,700		41,000
Accrued license payments - related party	50,000		39,538
Total current liabilities	243,023		316,131
Long term debt
TOTAL LIABILITIES	243,023		316,131
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding
Common Stock, $.001 par value, 200,000,000 shares authorized 58,868,713 and 58,325,169 shares issued and outstanding as of 6/30/12 and 12/31/11, respectively	58,869		58,325
Additional paid in capital	12,553,628		12,405,395
Additional paid in capital for shares to be issued	168,500	[1]
Accumulated deficit during development stage	(10,858,812)		(9,548,746)
Total shareholders' equity	1,922,185		2,914,974
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 2,165,208		$ 3,231,105

[1] Represents 550,000 shares of common stock